Growth hormone, IGF-I and cancer. Less intervention to avoid cancer? More intervention to prevent cancer?

Journal of Endocrinology

Volumn 162, Issue 3, 1999, Pages 321-330

  Holly, J M P ^a   Gunnell, D J ^b   Smith, G Davey ^b  

^a BRISTOL ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ESTRADIOL; GROWTH HORMONE; RECOMBINANT GROWTH FACTOR; SEX HORMONE BINDING GLOBULIN; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 3; TESTOSTERONE;

BREAST CANCER; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; COLORECTAL CANCER; GROWTH HORMONE BLOOD LEVEL; HEART FAILURE; HORMONE SUBSTITUTION; HUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; REVIEW; TURNER SYNDROME;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GROWTH HORMONE; HUMANS; INCIDENCE; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; NEOPLASMS; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RISK; RISK ASSESSMENT;

EID: 0032884082     PISSN: 00220795     EISSN: None     Source Type: Journal    
DOI: 10.1677/joe.0.1620321     Document Type: Review

References (78)

1. Albanes D, Jones DY, Schatzkin A, Micozzi MS & Taylor PR 1988 Adult stature and risk of cancer. Cancer Research 48 1658-1662.
2. Barres BA, Hart IK, Coles HSR, Burne JF, Voyvodic JT, Richardson WD & Raff MC 1992 Cell death and control of cell survival in the oligodendrocyte lineage. Cell 70 31-46.
3. Baserga R, Resnicoff M & Dews M 1997 The IGF-I receptor and cancer. Endocrine 7 99-102.
4. Bates P, Fisher R, Ward A, Richardson L, Hill DJ & Graham CF 1995 Mammary cancer in transgenic mice expressing insulin-like growth factor-II (IGF-II). British Journal of Cancer 72 1189-1193.
5. Bengtsson B-A, Eden S, Ernest I, Oden A & Sjogren B 1988 Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984. Acta Medica Scandinavica 223 327-335.
6. Besser M 1997 Growth hormone therapy in adults: a physician's personal view of the need for pharmacovigilance. Endocrinology and Metabolism 4 (Suppl) 87-88.
7. Blethen SL, Allen DB, Graves D, August G, Moshang T, Rosenfeld R, on behalf of the National Cooperative Growth Study 1996 Safety of recombinant deoxyribonucleic acid derived growth hormone: the National Cooperative Growth Study experience. Journal of Clinical Endocrinology and Metabolism 81 1704-1710.
8. Bohlke K, Cramer DW, Trichopoulos D & Mantzoros CS 1998 Insulin-like growth factor-I in relation to premenopausal ductal carcinoma in situ of the breast. Epidemiology 9 570-573.
9. Bradford Hill A 1965 The environment and disease: association or causation? Proceedings of the Royal Society of Medicine 58 295-300.
10. Cariani E, Dubois N, Lasserre C, Briand P & Brechet C 1991 Insulin-like growth factor II (IGF-II) mRNA expression during hepatocarcinogenesis in transgenic mice. Journal of Hepatology 13 220-226.
11. Carroll PV, Christ ER, Bengtsson BA, Carlsson L, Christiansen JS, Clemmons D, Hintz R, Ho K, Laron Z, Sizonenko P, Sonksen PH, Tanaka T & Thorner M 1998 Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. Journal of Clinical Endocrinology and Metabolism 83 382-395.
12. Cats A, Dullaart RP, Kliebeuker JH, Kuipers F, Sluiter WJ, Hardonk MJ & de Vries EG 1996 Increased epithelial cell proliferation in the colon of patients with acromegaly. Cancer Research 56 523-526.
13. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH & Pollak M 1998 Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279 563-566.
14. Christofori G, Naik P & Hanahan D 1994 A second signal supplied by insulin-like growth factor II in oncogene-induced tumorigenesis. Nature 369 414-418.
15. Chute CG, Willett WC, Colditz GA, Stampfer MJ, Baron JA, Rosner B & Speizer FE 1991 A prospective study of body mass, height and smoking on the risk of colorectal cancer in women. Cancer Causes and Control 2 117-124.
16. Cianfarani S, Tedeschi B, Germani D, Prete SP, Rossi P, Vernole P, Caporossi D & Boscerini B 1998 In vitro effects of growth hormone (GH) and insulin-like growth factor I and II (IGF-I and -II) on chromosome fragility and p53 protein expression in human lymphocytes. European Journal of Clinical Investigation 28 41-47.
17. Clark PA & Rogol AD 1996 Growth hormones and sex steroid interactions at puberty. Endocrinology and Metabolism Clinics of North America. 25 665-681.
18. Cohen SM & Ellwein LB 1990 Cell proliferation in carcinogenesis. Science 249 1007-1011.
19. Colao AM, Marzullo O, Ferone D, Spiezia S, Cerbone G, Marino V, Di Sarno A, Merola B & Lombardi G 1998 Prostatic hyperplasia: an unknown feature of acromegaly. Journal of Clinical Endocrinology and Metabolism 83 775-779.
20. Corpas E, Harman SM & Blackman MR 1993 Human growth hormone and human aging. Endocrine Reviews 14 20-39.
21. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G & Klocker H 1994 Androgen receptor activation in prostate tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Research 54 5474-5478.
22. Cuneo RC, Judd S, Wallace JD, Perry-Keene D, Burger H, Lim-Tio S, Strauss B, Stockigt J, Topliss D, Alford F, Hew L, Bode H, Conway A, Handelsman D, Dunn S, Boyages S, Wah Cheung N & Hurley D 1998 The Australian multicenter trial of growth hormone (GH) treatment in GH-deficient adults. Journal of Clinical Endocrinology and Metabolism 83 107-116.
23. Damon SE, Maddison L, Ware JL & Plymate SR 1998 Overexpression of an inhibitory insulin-like growth factor binding protein (IGFBP), IGFBP-4, delays onset of prostate tumor formation. Endocrinology 139 3456-3464.
24. Davenport ML, Clemmons DR, Miles MV, Camacho-Hubner C, D'Ercole AJ & Underwood LE 1990 Regulation of serum insulin-like growth factor-I (IGF-I) and IGF binding proteins during rat pregnancy. Endocrinology 127 1278-1286.
25. De Mellow JSM, Handelsman DJ & Baxter RC 1987 Short-term exposure to insulin-like growth factors stimulates testosterone production by testicular interstitial cells. Acta Endocrinologica 115 483-489.
26. Dorgan JF, Longcope C, Stephenson HE, Falk RT, Miller R, Franz C, Kahle L, Campbell WS, Tangrea JA & Schatzkin A 1997 Serum sex hormone levels are related to breast cancer risk in postmenopausal women. Environmental Health Perspectives 105 (Suppl 3) 583-585.
27. Early Breast Cancer Trialist Collaborative Group 1998 Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351 1451-1467.
28. Eriksson L, Frankenne F, Eden S, Hennen G & Von Schoultz B 1989 Growth hormone 24-h serum profiles during pregnancy - lack of pulsatility for the secretion of the placental variant. British Journal of Obstetrics and Gynaecology 96 949-953.
29. Fazio S, Sabatini D, Capaldo B, Vigorito C, Giordano A, Guida R, Pardo F, Biondi B & Sacca L 1996 A preliminary study of growth hormone in the treatment of dilated cardiomyopathy. New England Journal of Medicine 334 809-814.
30. Fisher DE 1994 Apoptosis in cancer therapy: crossing the threshold. Cell 78 539-542.
31. Frankel S, Gunnell DJ, Peters TJ, Maynard M & Davey Smith G 1998 Childhood energy intake and adult mortality from cancer: the Boyd Orr cohort study. British Medical Journal 316 499-504.
32. Gann PH, Hennekens CH & Stampfer MJ 1995 A prospective evaluation of plasma prostate specific antigen for detection of prostate cancer. Journal of the American Medical Association 273 289-294.
33. Gann PH, Hennekens CH, Ma J, Longcope C & Stampfer MJ 1996 Prospective study of sex hormone levels and risk of prostate cancer. Journal of the National Cancer Institute 88 1118-1126.
34. Gill ZP, Perks CM, Newcomb PVN & Holly JMP 1997 Insulin-like growth factor binding protein-3 (IGFBP-3) predisposes breast cancer cells to programmed cell death in a non-IGF dependent manner. Journal of Biological Chemistry 272 25602-25607.
35. Giovannucci E, Rim EB, Stampfer MJ, Colditz GA & Willett WC 1997 Height, body weight, and risk of prostate cancer. Cancer Epidemiology, Biomarkers and Prevention 6 557-563.
36. Giovannucci E, Rim EB, Stampfer MJ, Colditz GA & Willett WC 1998 Diabetes mellitus and risk of prostate cancer (United States). Cancer Causes and Control 9 3-9.
37. Giudice LA 1992 Insulin-like growth factors and ovarian follicular development. Endocrine Reviews 13 641-669.
38. Goodman-Gruen D & Barrett-Connor E 1997 Epidemiology of insulin-like growth factor-I in elderly men and women. The Rancho Bernardo Study. American Journal of Epidemiology 1997 145 970-976.
39. Gunnell DJ, Davey Smith G, Frankel S, Nanchahal K, Braddon FEM, Pemberton J & Peters TJ 1998a Childhood leg length and adult mortality: follow up of the Carnegie (Boyd Orr) Survey of Diet and Health in Pre-war Britain. Journal of Epidemiology and Community Health 52 142-152.
40. Gunnell DJ, Davey Smith G, Holly JMP & Frankel S 1998b Leg length and cancer risk: indirect evidence of an aetiological role for growth factors in the Boyd Orr cohort. British Medical Journal (In Press).
41. Hankinson SE, Willett WC, Manson JE, Hunter DJ, Colditz GA, Stampfer MJ, Longcope C & Speizer FE 1995 Alcohol, height, and adiposity in relation to estrogen and prolactin levels in postmenopausal women. Journal of the National Cancel Institute 87 1297-1302.
42. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE & Pollak M 1998 Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351 1393-1396.
43. Harrington EA, Bennett MR, Fanidi A & Evan GI 1994 c-Myc-induced apoptosis in fibroblasts is inhibited by specific cytokines. EMBO Journal 1994 13 3286-3295.
44. Harris JR, Lippman ME, Morrow M & Hellman S Eds 1996 Diseases of the Breast. Philadelphia: Lippincott-Raven Publishers.
45. Haymond MW & Mauras N 1996 The rationale for the use of recombinant human growth hormone and insulin-like growth factor-I for catabolic conditions in humans. Hormone Research 46 202-207.
46. Helle SI, Holly JMP, Tally M, Hall K, van der Stappen J & Lonning PE 1996 Influence of treatment with tamoxifen and change in tumor burden on the IGF-system in breast cancer patients. International Journal of Cancer 69 335-339.
47. Helle SI, Geisler J, Poulsen JP, Hestdal K, Meadows K, Collins W, Tveit KM, Viste A, Holly JMP & Lonning PE 1998 Micro-encapsulated octreotide pamoate in advanced gastrointestinal and pancreatic cancer: a phase I study. British Journal of Cancer 78 14-20.
48. Hunter DJ & Willett WC 1993 Diet, body size and breast cancer. Epidemiologic Reviews 15 110-132.
49. Invited Report of a Workshop 1998 Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency: summary statement of the Growth Hormone Research Society workshop on adult growth hormone deficiency. Journal of Clinical Endocrinology and Metabolism 83 379-381.
50. Jörgensen JOL, Moller N, Launtzen T & Christiansen JS 1990 Pulsatile versus continuous intravenous administration of growth hormone (GH) in GH-defident patients: effects on circulating insulin-like growth factor-I and metabolic indices. Journal of Clinical Endocrinology and Metabolism 70 1616-1623.
51. Lambe M, Hsieh C, Trichopoulos D, Ekbom A, Pavia M & Adami HO 1994 Transient increase in the risk of breast cancer after giving birth. New England Journal of Medicine 331 5-9.
52. Lancet 1998 News: Second drug said to reduce breast cancer risk. Lancet 351 1335.
53. Lee AV, Weng CN, Jackson JG & Yee D 1997 Activation of estrogen receptor mediated gene transcription by IGF-I in human breast cancer cells. Journal of Endocrinology 152 39-47.
54. Leon DA, Davey Smith G, Shipley M & Strachan D 1995 Adult height and mortality in London: early life, socioeconomic confounding, or shrinkage? Journal of Epidemiology and Community Health 49 5-9.
55. Loeb LA 1991 Mutator phenotype may be required for multistage carcinogenesis. Cancer Research 51 3075-3079.
56. Lucidi P, Lauteri M, Laureti S, Celleno R, Santoni S, Volpi E, Angeletti G, Santeusanio F & De Feo P 1998 A dose-response study of growth hormone (GH) replacement on whole body protein and lipid kinetics in GH-deficient adults. Journal of Clinical Endocrinology and Metabolism 83 353-357.
57. Maison P, Balkau B, Simon D, Chanson P, Rosselin G & Eschwege E 1998 Growth hormone as a risk for premature mortality in healthy subjects: data from the Paris prospective study. British Medical Journal 316 1132-1133.
58. Marcelli M, Haidacher SJ, Plymate SR & Birnbaum RS 1995 Altered growth and insulin-like growth factor-binding protein-3 production in PC-3 prostate carcinoma cells stably transfected with a constitutively active androgen receptor complementary deoxyribonudeic acid. Endocrinology 136 1040-1048.
59. Michels KB, Trichopoulos D, Robins JM, Robins JM, Rosner BA, Manson JE, Hunter DJ, Colditz GA, Hankinson SE, Speizer FE & Willett WC 1996 Birthweight as a risk factor for breast cancer. Lancet 348 1542-1546.
60. Nabarro JDN 1987 Acromegaly. Clinical Endocrinology 26 481-512.
61. Ng ST, Zhou J, Adesanya OO, Wang J, LeRoith D & Bondy CA 1997 Growth hormone treatment induces mammary gland hyperplasia in aging primates. Nature Medicine 3 1141-1144.
62. Orme SM, McNally R, Staines A, Cartwright RA & Belchetz PE 1996 Cancer incidence and mortality in acromegaly: a retrospective cohort study. Journal of Endocrinology 148 (Suppl) OC22.
63. Orme SM, McNally RJQ, Cartwright RA & Belchetz PE 1998 Mortality and cancer incidence in acromegaly: a retrospective cohort study. Journal of Clinical Endocrinology and Metabolism 83 2730-2734.
64. Orr-Weaver TL & Weinberg RA 1998 A checkpoint on the road to cancer. Nature 392 223-224.
65. Pritchard KI 1998 Is tamoxifen effective in prevention of breast cancer? Lancet 352 80-81.
66. Rajah R, Valentinis B & Cohen P 1997 Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-β1 on programmed cell death through a p53- and IGF-independent mechanism. Journal of Biological Chemistry 272 12181-12188.
67. Resnicoff M & Baserga R 1998 The role of the insulin-like growth factor I receptor in transformation and apoptosis. Annals of the New York Academy of Sciences 842 76-81.
68. Rogler CE, Yang D, Rossetti L, Donohoe J, Alt E, Chang CJ, Rosenfeld R, Neely K & Hintz R 1994 Altered body composition and increased frequency of diverse malignancies in insulin-like growth factor-II transgenic mice. Journal of Biological Chemistry 269 13779-13784.
69. Schirmacher P, Held WA, Yang D, Chisari FV, Rustum Y & Rogler CE 1993 Reactivation of insulin-like growth factor II during hepatocarcinogenesis in transgenic mice suggests a role in malignant growth. Cancer Research 52 2549-2556.
70. Smith-Warner SA, Spiegelman D, Shiaw-Shyuan Y, Van den Brandt PA, Folsom AR, Goldbohm A, Graham S, Holmberg L, Howe GR, Marshall JR, Miller AB, Potter JD, Speizer FE, Willett WC, Wolk A & Hunter DJ 1998 Alcohol and breast cancer in women. A pooled analysis of cohort studies. Journal of the American Medical Association 279 535-540.
71. Taback SP, Collu R, Deal CL, Guyda HJ, Salisbury S, Dean HJ & Van Vliet G 1996 Does growth hormone supplementation affect adult height in Turner's syndrome? Lancet 348 25-27.
72. Tedeschi B, Spadoni GL, Sanna ML, Vernole P, Caporossi D, Cianfarani S, Nicoletti B & Boscherini B 1993 Increased chromosome fragility in lymphocytes of short normal children treated with recombinant human growth hormone. Human Genetics 91 459-463.
73. Thissen J-P, Ketelslegers J-M & Underwood LE 1994 Nutritional regulation of the insulin-like growth factors. Endocrine Reviews 15 80-101.
74. Tibblin G, Eriksson M, Cnattingius S & Ekborn A 1995 High birthweight as a predictor of prostate cancer risk. Epidemiology 6 423-424.
75. Tornell J, Carlsson B, Pohjanen P, Wennbo H, Rymo L & Isaksson OGP 1992 High frequency of mammary adenocarcinomas in metallothionein promoter-human growth hormone transgenic mice created from two different strains of mice. Journal of Steroid Biochemistry and Molecular Biology 43 237-242.
76. Westley BR & May FEB 1994 Role of insulin-like growth factors in steroid modulated proliferation. Journal of Steroid Biochemistry and Molecular Biology 51 1-9.
77. Wolk A, Mantzoros CS, Andersson S-O, Bergstrom R, Signorello LB, Lagiou P, Adami H-O & Trichopoulos D 1998 Insulin-like growth factor I and prostate cancer risk: a population-based, case-control study. Journal of the National Cancer Institute 90 911-915.
78. Zumoff B 1997 The critical role of alcohol consumption in determining the risk of breast cancer with postmenopausal estrogen administration. Journal of Clinical Endocrinology and Metabolism 82 1656-1658.